Loading stock data…
Cabaletta Bio (CABA)
$2.69-0.03 (-1.10%)
Market ClosedLast close Jul 24
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cabaletta Bio, Inc. in the Healthcare sector is trading at $2.69 with a market capitalization of $467M. Wall Street consensus targets $13.38 (8 analysts), implying a +397.2% move over the next 12 months. The stock is currently 36% below its 52-week high of $4.23, remaining 5.9% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +397.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$44.30M↓ | -$42.61M↑ | -$46.59M↓ | -$45.91M↓ | -$37.14M |
| Net Income | -$43.52M↓ | -$41.92M↑ | -$44.87M↑ | -$45.13M↓ | -$35.94M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-s...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$467.15M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-169.82%
Volume
Today's trading volume
1.66M
Recent News
Kyverna Therapeutics Sinks 13%: Here’s Why
A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the question now is whether the selloff marks a buying opportunity or the start of a painful unwind.
How Cabaletta Bio (CABA) Is Turning Rese-cel Enrollment and New Financing Into a Clearer Autoimmune Cell Therapy Setup
Cabaletta Bio, Inc. (NASDAQ:CABA) is one of the small-cap stocks with potential to rise 1000 percent. The company’s 2026 story is focused on rese-cel, an experimental cell therapy being developed for autoimmune diseases, where the immune system mistakenly attacks the body. In its May 14 first-quarter update, Cabaletta said enrollment was progressing in a small […]
FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases
By Karen Roman Imviva Biotech said the FDA cleared its Investigational New Drug application for CTA313, a dual-targeted CAR-T therapy for the treatment of B-cell-mediated autoimmune diseases. Phase 1b of this clinical trial will study CTA313 in patients with systemic lupus erythematosus, progressive multiple sclerosis, and autoimmune encephalitis, among other autoimmune conditions, the company stated. […] The post FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases appeared first on Ex
Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases
Cabaletta Bio Inc. (NASDAQ:CABA) is one of the top penny stocks to buy in investors’ stock portfolio. On May 14, Cabaletta Bio Inc. (NASDAQ:CABA) delivered positive clinical and translational data from the first four patients in the lowest dose cohort evaluating preconditioning-free (PC-free) rese-cel, an investigational, autologous CAR T cell therapy for the treatment of […]
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?
Here is how Cabaletta Bio, Inc. (CABA) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.